Gryphon has a set of protein engineering technologies for creating even very large synthetic proteins, useful for modifying existing protein therapeutics to improve them as drugs, creating multivalent artificial therapeutics and vaccines, and doing rapid structure-function analysis of newly uncovered proteins.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.